WO2012163941A3 - Marker for the detection and classification of leukemia from blood samples - Google Patents

Marker for the detection and classification of leukemia from blood samples Download PDF

Info

Publication number
WO2012163941A3
WO2012163941A3 PCT/EP2012/060097 EP2012060097W WO2012163941A3 WO 2012163941 A3 WO2012163941 A3 WO 2012163941A3 EP 2012060097 W EP2012060097 W EP 2012060097W WO 2012163941 A3 WO2012163941 A3 WO 2012163941A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
marker
blood samples
marker gene
classification
Prior art date
Application number
PCT/EP2012/060097
Other languages
French (fr)
Other versions
WO2012163941A2 (en
Inventor
Oliver LAULE
Stefan BLEULER
Philip Zimmermann
Original Assignee
Nebion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nebion Ag filed Critical Nebion Ag
Publication of WO2012163941A2 publication Critical patent/WO2012163941A2/en
Publication of WO2012163941A3 publication Critical patent/WO2012163941A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for detecting leukemia from patient samples, preferably blood samples, and to preferably classify it into specific types of leukemia, comprising the steps of: (a) determining the expression level of at least one marker gene; and (b) comparing the expression level of the at least one marker gene to a reference to predict leukemia, preferably a specific type of leukemia; wherein the at least one marker gene corresponds to at least one of the genes listed in one or more of Tables I to VI and/or is represented by at least one probe set or at least one target sequence listed in one or more of Tables I to VI. The invention further relates to a kit to perform the method, to the use of the marker genes and to a reagent for detecting leukemia.
PCT/EP2012/060097 2011-05-30 2012-05-30 Marker for the detection and classification of leukemia from blood samples WO2012163941A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH00921/11 2011-05-30
CH9212011 2011-05-30

Publications (2)

Publication Number Publication Date
WO2012163941A2 WO2012163941A2 (en) 2012-12-06
WO2012163941A3 true WO2012163941A3 (en) 2013-02-28

Family

ID=46331243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/060097 WO2012163941A2 (en) 2011-05-30 2012-05-30 Marker for the detection and classification of leukemia from blood samples

Country Status (1)

Country Link
WO (1) WO2012163941A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230287510A1 (en) * 2020-08-10 2023-09-14 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
CN115820855B (en) * 2022-10-12 2023-07-21 南昌大学第二附属医院 Application of HDC, SMPDL3A, IRF and AQP3 in preparation of reagent and kit for diagnosing CML

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
WO2010056351A2 (en) * 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
WO2010056351A2 (en) * 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACHER U ET AL: "Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies", CANCER TREATMENT REVIEWS, SAUNDERS, US, vol. 36, no. 8, 1 December 2010 (2010-12-01), pages 637 - 646, XP027487300, ISSN: 0305-7372, [retrieved on 20100608], DOI: 10.1016/J.CTRV.2010.05.002 *
DATABASE Genbank [Online] NCBI; 23 October 2006 (2006-10-23), "Homo sapiens coiled-coil domain containing 81 mRNA (cDNA clone)", XP002683874, retrieved from ncbi.nlm.nih.gov Database accession no. BC126412 *
S. CHIARETTI ET AL: "Gene Expression Profiles of B-lineage Adult Acute Lymphocytic Leukemia Reveal Genetic Patterns that Identify Lineage Derivation and Distinct Mechanisms of Transformation", CLINICAL CANCER RESEARCH, vol. 11, no. 20, 15 October 2005 (2005-10-15), pages 7209 - 7219, XP055038821, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-04-2165 *
VASCONCELOS Y ET AL: "Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 19, no. 11, 25 August 2005 (2005-08-25), pages 2002 - 2005, XP002367298, ISSN: 0887-6924, DOI: 10.1038/SJ.LEU.2403865 *

Also Published As

Publication number Publication date
WO2012163941A2 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
WO2012096545A3 (en) Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
MX341517B (en) Pancreatic cancer biomarkers and uses thereof.
WO2013113012A3 (en) Methods for profiling and quantitating cell-free rna
RU2017101174A (en) KIT OR DEVICE FOR LIVER CANCER DETECTION AND DETECTION METHOD
EA030186B9 (en) Method for performing quantitation assays
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IL204288A (en) Copy number variation determination, methods and systems
WO2012095639A3 (en) Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence
WO2009057695A1 (en) Method for detection of adenoma or cancer by genetic analysis
NO20083957L (en) DNA conformation
EP3118326A3 (en) Molecular marker for cancer stem cell
EP3511717A3 (en) Biodosimetry panels and methods
MX2014004860A (en) Lung cancer biomarkers and uses thereof.
WO2013172779A3 (en) Method for indicating the presence or non-presence of prostate cancer
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
MX2014006118A (en) Detecting analytes.
MX2015001961A (en) Assay methods and systems.
EP2584045A4 (en) Method for detection of colorectal tumor
WO2012174119A3 (en) Compositions and methods for detection of cronobacter spp. and cronobacter species and strains
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2013090386A3 (en) Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample
GB201014837D0 (en) Biomarker signatures and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12729040

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12729040

Country of ref document: EP

Kind code of ref document: A2